Avalon Globocare Corp
ALBT1.960USD
-0.130-6.22%
Fechamento 11/04, 16:00（ET）Cotações atrasadas em 15 min
4.60MValor de mercado
PerdaP/L TTM
Mais detalhes de Avalon Globocare Corp Empresa
Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering transformative, precision diagnostics and clinical laboratory services. The Company offers diagnostic testing utilizing proprietary technology to deliver genetics-driven results. It operates through two segments: Real property rental and Lab Services MSO. Lab Services MSO segment is focused on delivering services related to toxicology and wellness testing and provides a portfolio of diagnostic tests including drug testing, toxicology, and a range of test services, from general bloodwork to anatomic pathology, and urine toxicology. Its capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, and sexually transmitted disease testing. The Lab Services MSO segment is also focused on the commercialization of genetic-based proprietary testing. It is also exploring the commercialization and development of a versatile breathalyzer system, KetoAir breathalyzer.
Informações de Avalon Globocare Corp
Código da empresaALBT
Nome da EmpresaAvalon Globocare Corp
Data de listagemFeb 22, 2016
CEODr. David Jin, M.D., Ph.D.
Número de funcionários5
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 22
Endereço4400 Route 9
CidadeFREEHOLD
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal07728
Telefone17327804400
Sitehttps://www.avalon-globocare.com/
Código da empresaALBT
Data de listagemFeb 22, 2016
CEODr. David Jin, M.D., Ph.D.
Executivos da empresa Avalon Globocare Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Wenzhao (Daniel) Lu
Mr. Wenzhao (Daniel) Lu
Chairman of the Board of Directors
Chairman of the Board of Directors
238.93K
--
Dr. David Jin, M.D., Ph.D.
Dr. David Jin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
103.00K
--
Ms. Meng Li
Ms. Meng Li
Chief Operating Officer, Company Secretary
Chief Operating Officer, Company Secretary
34.33K
--
Mr. Steven Andrew Sanders, J.D.
Mr. Steven Andrew Sanders, J.D.
Independent Director
Independent Director
--
--
Ms. Lourdes Felix
Ms. Lourdes Felix
Independent Director
Independent Director
--
--
Ms. Luisa Ingargiola
Ms. Luisa Ingargiola
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Wilbert J. (Billy) Tauzin, II
Mr. Wilbert J. (Billy) Tauzin, II
Director
Director
--
--
Dr. The Hon. Tevi Troy, Ph.D.
Dr. The Hon. Tevi Troy, Ph.D.
Independent Director
Independent Director
--
--
Mr. William B. Stilley, III
Mr. William B. Stilley, III
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Wenzhao (Daniel) Lu
Mr. Wenzhao (Daniel) Lu
Chairman of the Board of Directors
Chairman of the Board of Directors
238.93K
--
Dr. David Jin, M.D., Ph.D.
Dr. David Jin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
103.00K
--
Ms. Meng Li
Ms. Meng Li
Chief Operating Officer, Company Secretary
Chief Operating Officer, Company Secretary
34.33K
--
Mr. Steven Andrew Sanders, J.D.
Mr. Steven Andrew Sanders, J.D.
Independent Director
Independent Director
--
--
Ms. Lourdes Felix
Ms. Lourdes Felix
Independent Director
Independent Director
--
--
Ms. Luisa Ingargiola
Ms. Luisa Ingargiola
Chief Financial Officer
Chief Financial Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 3 de set
Atualizado em: qua, 3 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Lu (Wenzhao)
6.23%
Jin (David)
2.69%
Vision Capital NY, Inc.
2.61%
Li (Meng)
0.90%
Geode Capital Management, L.L.C.
0.54%
Outro
87.05%
Investidores
Investidores
Proporção
Lu (Wenzhao)
6.23%
Jin (David)
2.69%
Vision Capital NY, Inc.
2.61%
Li (Meng)
0.90%
Geode Capital Management, L.L.C.
0.54%
Outro
87.05%
Tipos de investidores
Investidores
Proporção
Individual Investor
9.84%
Corporation
2.61%
Investment Advisor
0.66%
Investment Advisor/Hedge Fund
0.54%
Research Firm
0.03%
Outro
86.33%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
31
47.28K
1.23%
-3.08K
2025Q2
37
494.33K
14.25%
+85.10K
2025Q1
39
494.33K
24.18%
+84.18K
2024Q4
39
426.83K
39.01%
+28.37K
2024Q3
38
465.14K
44.22%
+32.28K
2024Q2
37
431.58K
58.50%
+7.86K
2024Q1
35
421.26K
56.90%
-5.41K
2023Q4
36
425.06K
58.60%
-685.00
2023Q3
43
423.55K
58.41%
-5.26K
2023Q2
52
423.10K
61.82%
-6.80K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Lu (Wenzhao)
238.93K
6.23%
+9.00
+0.00%
Mar 31, 2025
Jin (David)
103.00K
2.69%
--
--
Mar 31, 2025
Vision Capital NY, Inc.
100.00K
2.61%
+100.00K
--
Mar 31, 2025
Li (Meng)
34.33K
0.9%
+1.00
+0.00%
Mar 31, 2025
Geode Capital Management, L.L.C.
9.34K
0.24%
--
--
Aug 31, 2025
Equitable Holdings, Inc.
14.22K
0.37%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.58K
0.04%
--
--
Aug 31, 2025
UBS Financial Services, Inc.
4.20K
0.11%
+1.64K
+64.05%
Jun 30, 2025
Tauzin (Wilbert J II)
1.04K
0.03%
+1.04K
--
Mar 31, 2025
Citi Investment Research (US)
951.00
0.02%
+951.00
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Jan 04, 2023
Merger
10→1
Jan 04, 2023
Merger
10→1
Data
Tipo
Proporção
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Jan 04, 2023
Merger
10→1
Jan 04, 2023
Merger
10→1
Jan 04, 2023
Merger
10→1
Jan 04, 2023
Merger
10→1
